CN104168907A - β-抑制蛋白效应器及其组合物与使用方法 - Google Patents

β-抑制蛋白效应器及其组合物与使用方法 Download PDF

Info

Publication number
CN104168907A
CN104168907A CN201380014614.9A CN201380014614A CN104168907A CN 104168907 A CN104168907 A CN 104168907A CN 201380014614 A CN201380014614 A CN 201380014614A CN 104168907 A CN104168907 A CN 104168907A
Authority
CN
China
Prior art keywords
peptide
peptidomimetic
pro
alanine
isoleucine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380014614.9A
Other languages
English (en)
Chinese (zh)
Inventor
丹尼斯·山下
陈小涛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trevena Inc
Original Assignee
Trevena Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trevena Inc filed Critical Trevena Inc
Publication of CN104168907A publication Critical patent/CN104168907A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201380014614.9A 2012-01-31 2013-01-30 β-抑制蛋白效应器及其组合物与使用方法 Pending CN104168907A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261592887P 2012-01-31 2012-01-31
US61/592,887 2012-01-31
PCT/US2013/023808 WO2013116312A1 (en) 2012-01-31 2013-01-30 ß-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF

Publications (1)

Publication Number Publication Date
CN104168907A true CN104168907A (zh) 2014-11-26

Family

ID=48870731

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380014614.9A Pending CN104168907A (zh) 2012-01-31 2013-01-30 β-抑制蛋白效应器及其组合物与使用方法

Country Status (14)

Country Link
US (2) US8946142B2 (cg-RX-API-DMAC7.html)
EP (1) EP2809337A4 (cg-RX-API-DMAC7.html)
JP (1) JP6225121B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140132340A (cg-RX-API-DMAC7.html)
CN (1) CN104168907A (cg-RX-API-DMAC7.html)
AU (1) AU2013215269A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014018709A8 (cg-RX-API-DMAC7.html)
CA (1) CA2862933A1 (cg-RX-API-DMAC7.html)
EA (1) EA201491455A1 (cg-RX-API-DMAC7.html)
HK (1) HK1203379A1 (cg-RX-API-DMAC7.html)
IL (1) IL233826A0 (cg-RX-API-DMAC7.html)
MX (1) MX2014009233A (cg-RX-API-DMAC7.html)
NZ (1) NZ627995A (cg-RX-API-DMAC7.html)
WO (1) WO2013116312A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013116312A1 (en) * 2012-01-31 2013-08-08 Trevena, Inc. ß-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF
EP3208861A1 (en) 2016-02-19 2017-08-23 Novaled GmbH Electron transport layer comprising a matrix compound mixture for an organic light-emitting diode (oled)
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010077339A2 (en) * 2008-12-29 2010-07-08 Trevena, Inc. β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF
WO2011163619A1 (en) * 2010-06-24 2011-12-29 Trustees Of Tufts College Niacin mimetics, and methods of use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3925345A (en) * 1974-05-10 1975-12-09 Francis Merlin Bumpus (sar' 1',thr' 8'+9 angiotensin ii as an angiotensin antagonist
US3932624A (en) 1974-06-17 1976-01-13 Morton-Norwich Products, Inc. Method for prolonging the inhibitory effect of saralasin on angiotensin II
JPS5825980B2 (ja) 1976-02-12 1983-05-31 ヤマサ醤油株式会社 サイクリックヌクレオチドの定量法
US4547489A (en) 1984-06-11 1985-10-15 Ortho Pharmaceutical Corporation Conformationally restricted thymopentin-like compounds
US5182264A (en) 1986-03-07 1993-01-26 Schering Corporation Angiotensin II receptor blockers as antiglaucoma agents
DE68903907T2 (de) * 1988-09-05 1993-06-09 Sankyo Co Cyclisches peptid, seine herstellung und seine verwendung zur behandlung von cardiovasculaeren stoerungen.
GB8822483D0 (en) 1988-09-24 1988-10-26 Medical Res Council Developments relating to mas oncogene
US5401629A (en) 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal
EP0608212A1 (en) 1990-08-27 1994-08-03 Peptide Technology Ltd Method of treating viral infection
EP0498361A3 (en) 1991-02-06 1992-09-02 Schering Corporation Combination of an angiotensin ii antagonist or renin inhibitor with a neutral endopeptidase inhibitor
US5955430A (en) 1993-09-24 1999-09-21 University Of Southern California Use of angiotensin II fragments and analogs thereof in tissue repair
PT730465E (pt) 1993-09-24 2002-06-28 Univ Southern California Utilizacao de angiotensina iii e de analogos desta em cicatrizacao de tecidos
US5958884A (en) 1997-04-11 1999-09-28 The Brigham And Women's Hospital, Inc. Compositions and methods for treating erectile dysfunction
ATE268782T1 (de) 1997-12-12 2004-06-15 Univ Southern California Zusammensetzungen zur wundheilung
US20040214836A1 (en) 1998-05-29 2004-10-28 Cheresh David A. Method of treatment of myocardial infarction
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US20050202029A1 (en) 2003-10-03 2005-09-15 The Board Of Trustees Of The Leland Stanford Junior University Family of cystatin-related chemoattractant proteins
US20070286863A1 (en) 2006-05-17 2007-12-13 Christopher Sinal CMKLR regulation of adipogenesis and adipocyte metabolic function
WO2008130217A1 (en) 2006-08-08 2008-10-30 Applied Nanosystems B.V. Cyclic angiotensin analogs
GB0705488D0 (en) 2007-03-22 2007-05-02 Isis Innovation Treatment of inflammation and/or endotoxic shock
US8038992B2 (en) 2008-05-10 2011-10-18 The Board Of Trustees Of The Leland Stanford Junior University Target for regulating multiple sclerosis
US20100092974A1 (en) 2008-08-15 2010-04-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for modulators of ccrl2
US8293925B2 (en) 2009-09-21 2012-10-23 Chemocentryx, Inc. Pyrrolidinone carboxamide derivatives
WO2013116312A1 (en) * 2012-01-31 2013-08-08 Trevena, Inc. ß-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010077339A2 (en) * 2008-12-29 2010-07-08 Trevena, Inc. β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF
CN102333536A (zh) * 2008-12-29 2012-01-25 特维那公司 β-抑制蛋白效应器和组合物以及其应用方法
WO2011163619A1 (en) * 2010-06-24 2011-12-29 Trustees Of Tufts College Niacin mimetics, and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J.SAMANEN,ET AL: "An Investigation of Angiotensin I1 Agonist and Antagonist Analogues with 5,5-Dimethylth iazolidine-4-carboxylicA cid and Other Constrained Amino Acids", 《J. MED. CHEM》 *
JONATHAN D. VIOLIN,ET AL: "Selectively Engaging β-Arrestins at the Angiotensin II Type 1 Receptor Reduces Blood Pressure and Increases Cardiac Performance", 《THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS》 *

Also Published As

Publication number Publication date
MX2014009233A (es) 2015-05-15
HK1203379A1 (en) 2015-10-30
US20130196902A1 (en) 2013-08-01
BR112014018709A8 (pt) 2017-07-11
EP2809337A1 (en) 2014-12-10
JP2015506960A (ja) 2015-03-05
WO2013116312A1 (en) 2013-08-08
KR20140132340A (ko) 2014-11-17
BR112014018709A2 (cg-RX-API-DMAC7.html) 2017-06-20
CA2862933A1 (en) 2013-08-08
EA201491455A1 (ru) 2015-01-30
IL233826A0 (en) 2014-09-30
JP6225121B2 (ja) 2017-11-01
US8946142B2 (en) 2015-02-03
NZ627995A (en) 2016-12-23
AU2013215269A1 (en) 2014-08-21
US20150105316A1 (en) 2015-04-16
EP2809337A4 (en) 2016-05-11

Similar Documents

Publication Publication Date Title
US9534017B2 (en) Beta-arrestin effectors and compositions and methods of use thereof
Gerbier et al. Development of original metabolically stable apelin‐17 analogs with diuretic and cardiovascular effects
CA3149581A1 (en) Q-er peptide
US8946142B2 (en) Beta-arrestin effectors and compositions and methods of use thereof
Jones et al. Charge delocalisation and the design of novel mastoparan analogues: enhanced cytotoxicity and secretory efficacy of [Lys5, Lys8, Aib10] MP
US20240025949A1 (en) Beta-Arrestin Effectors and Compositions and Methods of Use Thereof
WO2016196750A1 (en) Beta-arrestin effectors and compositions and methods of use thereof
US20210324005A1 (en) Beta-Arrestin Effectors and Compositions and Methods of Use Thereof
HK1162955B (en) Beta-arrestin effectors and compositions and methods of use thereof
EP3849583B1 (en) PEPTIDES FOR THE TREATMENT OF NEOVASCULAR EYE DISEASES
Zhang Functional studies of kisspeptin analogues and the human kisspeptin receptor
Wasilewski Absence of V1AR Alters Cardiac Function at Baseline and Following Acute Cardiac Injury
Lee Characterizing the structure and function of the cytoplasmic domains of Ptch1
Itturioz et al. Identification and pharmacological properties of E339–3D6, the first nonpeptidic apelin receptor agonist
Deshotels Modulation of angiotensin-converting enzyme 2 (ACE2) expression, subcellular localization, and enzymatic activity by angiotensin II: Implication in neurogenic hypertension

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20141126